default author photo

Linghua Wang

University of Texas at Houston - Department of Genomic Medicine

1515 Holocombe Blvd

Houston, TX 77030

United States

SCHOLARLY PAPERS

2

DOWNLOADS

193

TOTAL CITATIONS

1

Scholarly Papers (2)

1.

Efficacy of Pembrolizumab in Patients with Advanced Rare Cancers

Number of pages: 41 Posted: 31 May 2019
University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, Baylor College of Medicine, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston, Health Science Center at Houston (UTHealth), MD Anderson Cancer Center, Department of Radiology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Thoracic/Head and Neck Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas Rio Grande Valley (UTRGV) (Formerly University of Texas-Pan American), University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, R Simon Consulting, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - MD Anderson Cancer Center and University of Texas at Houston - MD Anderson Cancer Center
Downloads 152 (488,442)

Abstract:

Loading...

2.

Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma

Number of pages: 72 Posted: 18 Mar 2020
University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Surgical Oncology, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center - Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, Jackson Laboratory for Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center - Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center - Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, University of Texas at Houston - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Molecular and Cellular Oncology and University of Texas MD Anderson Cancer Center - Department of Genomic Medicine
Downloads 41 (1,170,409)
Citation 1

Abstract:

Loading...

Melanoma, KMT2D, Enhancer, Glycolysis, Chromatin, Epigenetics